SG Trading Solutions LLC Invests $1.06 Million in Abbott Laboratories $ABT

SG Trading Solutions LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,487 shares of the healthcare product maker’s stock, valued at approximately $1,063,000.

A number of other institutional investors have also added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter valued at approximately $26,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Harbor Capital Advisors Inc. bought a new position in Abbott Laboratories in the fourth quarter worth $27,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 0.0%

NYSE:ABT opened at $88.48 on Friday. The stock has a 50-day simple moving average of $90.39 and a 200 day simple moving average of $106.73. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06. The company has a market cap of $154.12 billion, a PE ratio of 24.78, a PEG ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ABT shares. Raymond James Financial decreased their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Stifel Nicolaus reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday. Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Piper Sandler reduced their target price on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.30.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.